Ryvu received PLN 22.25 million funding recommendation. Ryvu Therapeutics stock trades 1,959 shares

Published on 10/08/2026 at 11:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Half-year revenue fell 8.73 percent to PLN 38.70 million. Ryvu Therapeutics stock costs EUR 3.68 on October 8, 2026 versus EUR 3.67, plus 0.27 percent.

Ryvu Therapeutics, PLSELVT00013, Illustration mit AI erstellt.

Ryvu Therapeutics (ISIN PLSELVT00013) had received a PLN 22.25 million funding recommendation for DUALIS, while 1,959 shares traded on the Warsaw Stock Exchange on October 8, 2026. The recommendation dated September 7, 2026 covered a PLN 30.86 million project, according to PAP. At Lang & Schwarz, the stock was trading at EUR 3.68 on October 8, 2026, plus 0.27 percent versus EUR 3.67.

DUALIS funding remains conditional

The DUALIS platform is designed to accelerate discovery of new bivalent payloads for antibody drug conjugates in oncology. The planned implementation period is 54 months, and the recommended funding could reduce Ryvu's use of its own cash if the company signs the formal agreement.

Parkiet reported on October 8, 2026 that Ryvu's project was among biotechnology initiatives recommended for support under the SMART Path program. The grant therefore strengthens the financing backdrop, but it is not equivalent to cash already received.

Revenue fell as costs declined

In the first half of 2026, operating revenue including grants fell 8.73 percent to PLN 38.70 million from PLN 42.40 million in the first half of 2025, according to Strefa Inwestorow. Operating costs excluding the valuation of NodThera interests and noncash share-based compensation fell to PLN 67.60 million from PLN 95.50 million, a 29.32 percent decline.

The same half-year report put adjusted net loss attributable to ordinary shareholders at PLN 25.50 million, down from PLN 57.10 million in the first half of 2025. The improvement in costs and adjusted loss is material for the cash runway, while the recommended DUALIS funding still requires a signed agreement.

Stock remains near the lower end

Finance data showed Ryvu's GPW quote at PLN 16.26 on October 8, 2026 at 10:52 a.m. CEST, with a PLN 13.64 to PLN 31.90 52-week range and PLN 375.9 million market capitalization. The separate euro quote at Lang & Schwarz was EUR 3.68 at 11:04 a.m. CEST, so the two venues should not be combined into one price comparison.

Ryvu Therapeutics is a clinical-stage biotechnology company focused on small-molecule oncology therapies. Its stock trades on the GPW under RVU and is included in the sWIG80 index. The further course of trading is shown by the continuously updated real-time quote of Ryvu Therapeutics stock.